How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
37
TAK Quote, Financials, Valuation and Earnings
Last price:
$13.17
Seasonality move
:
6.06%
Day range:
$13.09 - $13.19
52-week range:
$12.58 - $15.08
Dividend yield:
4.7%
P/E ratio:
21.79x
P/S ratio:
1.39x
P/B ratio:
0.86x
Volume:
968.4K
Avg. volume:
1.8M
1-year change:
-6.26%
Market cap:
$41.8B
Revenue:
$29.5B
EPS (TTM):
$0.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
$7.2B | -- | 0.1% | -- | $16.03 |
|
ALPMY
Astellas Pharma
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | -- | -- | $28.11 |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
$13.17 | $16.03 | $41.8B | 21.79x | $0.33 | 4.7% | 1.39x |
|
ALPMY
Astellas Pharma
|
$9.65 | -- | $17.3B | 165.47x | $0.25 | 4.88% | 1.52x |
|
HCM
HUTCHMED (China)
|
$14.30 | $28.11 | $2.4B | 30.00x | $0.00 | 0% | 5.93x |
|
HLOSF
Healios KK
|
$1.35 | -- | $121.7M | -- | $0.00 | 0% | 32.00x |
|
PPTDF
PeptiDream
|
$17.15 | -- | $2.2B | 20.38x | $0.00 | 0% | 7.14x |
|
SOLTF
Nxera Pharma
|
$6.16 | -- | $553.6M | -- | $0.00 | 0% | 2.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
42.19% | 0.312 | 78.44% | 0.68x |
|
ALPMY
Astellas Pharma
|
36.57% | -0.037 | -- | 0.71x |
|
HCM
HUTCHMED (China)
|
9.99% | -0.098 | 2.79% | 2.39x |
|
HLOSF
Healios KK
|
65.07% | -0.707 | 34.39% | 1.33x |
|
PPTDF
PeptiDream
|
25.75% | -2.667 | 6.45% | 3.28x |
|
SOLTF
Nxera Pharma
|
48.92% | 1.984 | 55.24% | 3.73x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
$5.3B | $1.8B | 2.37% | 4.01% | 15.97% | $1.3B |
|
ALPMY
Astellas Pharma
|
$2.5B | $306.7M | 0.66% | 0.97% | 11.62% | $366.7M |
|
HCM
HUTCHMED (China)
|
-- | -- | -5.04% | -5.49% | -- | -- |
|
HLOSF
Healios KK
|
$2.8M | -$1.8M | -55.94% | -137.21% | -24.5% | -$4.8M |
|
PPTDF
PeptiDream
|
$17.4M | -$854.5K | 24.02% | 34.66% | -1.5% | $173.8M |
|
SOLTF
Nxera Pharma
|
$48.9M | $5.4M | -2.75% | -5.58% | 11.44% | $10.3M |
Takeda Pharmaceutical vs. Competitors
-
Which has Higher Returns TAK or ALPMY?
Astellas Pharma has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of 7.95%. Takeda Pharmaceutical's return on equity of 4.01% beat Astellas Pharma's return on equity of 0.97%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B ALPMYAstellas Pharma80.74% $0.13 $16.6B -
What do Analysts Say About TAK or ALPMY?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand Astellas Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Astellas Pharma, analysts believe Takeda Pharmaceutical is more attractive than Astellas Pharma.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 ALPMYAstellas Pharma0 0 0 -
Is TAK or ALPMY More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison Astellas Pharma has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.161%.
-
Which is a Better Dividend Stock TAK or ALPMY?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. Astellas Pharma offers a yield of 4.88% to investors and pays a quarterly dividend of $0.25 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Astellas Pharma pays out 684.38% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TAK or ALPMY?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Astellas Pharma quarterly revenues of $3B. Takeda Pharmaceutical's net income of $619.7M is higher than Astellas Pharma's net income of $241.2M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while Astellas Pharma's PE ratio is 165.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 1.52x for Astellas Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M ALPMYAstellas Pharma1.52x 165.47x $3B $241.2M
-
Which has Higher Returns TAK or HCM?
HUTCHMED (China) has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of --. Takeda Pharmaceutical's return on equity of 4.01% beat HUTCHMED (China)'s return on equity of -5.49%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B HCMHUTCHMED (China)-- -- $834.1M -
What do Analysts Say About TAK or HCM?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand HUTCHMED (China) has an analysts' consensus of $28.11 which suggests that it could grow by 96.54%. Given that HUTCHMED (China) has higher upside potential than Takeda Pharmaceutical, analysts believe HUTCHMED (China) is more attractive than Takeda Pharmaceutical.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 HCMHUTCHMED (China)9 2 0 -
Is TAK or HCM More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.86%.
-
Which is a Better Dividend Stock TAK or HCM?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or HCM?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than HUTCHMED (China) quarterly revenues of --. Takeda Pharmaceutical's net income of $619.7M is higher than HUTCHMED (China)'s net income of --. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while HUTCHMED (China)'s PE ratio is 30.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 5.93x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M HCMHUTCHMED (China)5.93x 30.00x -- --
-
Which has Higher Returns TAK or HLOSF?
Healios KK has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -107.23%. Takeda Pharmaceutical's return on equity of 4.01% beat Healios KK's return on equity of -137.21%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B HLOSFHealios KK86.35% -$0.04 $57.8M -
What do Analysts Say About TAK or HLOSF?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 HLOSFHealios KK0 0 0 -
Is TAK or HLOSF More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TAK or HLOSF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or HLOSF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Healios KK quarterly revenues of $3.2M. Takeda Pharmaceutical's net income of $619.7M is higher than Healios KK's net income of -$3.4M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 32.00x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M HLOSFHealios KK32.00x -- $3.2M -$3.4M
-
Which has Higher Returns TAK or PPTDF?
PeptiDream has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -5.57%. Takeda Pharmaceutical's return on equity of 4.01% beat PeptiDream's return on equity of 34.66%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B PPTDFPeptiDream47.13% -$0.02 $551.4M -
What do Analysts Say About TAK or PPTDF?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than PeptiDream, analysts believe Takeda Pharmaceutical is more attractive than PeptiDream.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 PPTDFPeptiDream0 0 0 -
Is TAK or PPTDF More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.
-
Which is a Better Dividend Stock TAK or PPTDF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or PPTDF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than PeptiDream quarterly revenues of $36.8M. Takeda Pharmaceutical's net income of $619.7M is higher than PeptiDream's net income of -$2.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M PPTDFPeptiDream7.14x 20.38x $36.8M -$2.1M
-
Which has Higher Returns TAK or SOLTF?
Nxera Pharma has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of 12.96%. Takeda Pharmaceutical's return on equity of 4.01% beat Nxera Pharma's return on equity of -5.58%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B SOLTFNxera Pharma78.44% $0.09 $928.9M -
What do Analysts Say About TAK or SOLTF?
Takeda Pharmaceutical has a consensus price target of $16.03, signalling upside risk potential of 20.8%. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 SOLTFNxera Pharma0 0 0 -
Is TAK or SOLTF More Risky?
Takeda Pharmaceutical has a beta of 0.498, which suggesting that the stock is 50.209% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.345%.
-
Which is a Better Dividend Stock TAK or SOLTF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.7%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or SOLTF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Takeda Pharmaceutical's net income of $619.7M is higher than Nxera Pharma's net income of $8.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.79x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.39x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M SOLTFNxera Pharma2.79x -- $62.4M $8.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
